Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Total Liabilities
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has total liabilities worth CN¥2.41 Billion CNY (≈ $352.93 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Luoxin Pharmaceuticals Group Stock Co Lt long-term investment allocation to see how much of total assets are deployed in long-term investments.
Luoxin Pharmaceuticals Group Stock Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Luoxin Pharmaceuticals Group Stock Co Lt total assets.
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Total Liabilities
The table below lists competitors of Luoxin Pharmaceuticals Group Stock Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Harvia Oyj
HE:HARVIA
|
Finland | €140.74 Million |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
China | CN¥2.11 Billion |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
China | CN¥1.50 Billion |
|
Shenzhen Textile Holdings Co Ltd
SHE:000045
|
China | CN¥1.17 Billion |
|
Chongqing Gangjiu Co Ltd
SHG:600279
|
China | CN¥5.14 Billion |
|
Plato Income Maximiser Ltd
AU:PL8
|
Australia | AU$10.14 Million |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
F:2CDA
|
Germany | €5.44 Billion |
|
Aucma Co Ltd
SHG:600336
|
China | CN¥5.23 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Luoxin Pharmaceuticals Group Stock Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Luoxin Pharmaceuticals Group Stock Co Lt to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Luoxin Pharmaceuticals Group Stock Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below shows the annual total liabilities of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.49 Billion ≈ $364.31 Million |
-13.45% |
| 2024-12-31 | CN¥2.88 Billion ≈ $420.93 Million |
+13.03% |
| 2023-12-31 | CN¥2.54 Billion ≈ $372.41 Million |
-46.99% |
| 2022-12-31 | CN¥4.80 Billion ≈ $702.59 Million |
+0.85% |
| 2021-12-31 | CN¥4.76 Billion ≈ $696.69 Million |
+41.22% |
| 2020-12-31 | CN¥3.37 Billion ≈ $493.33 Million |
-3.64% |
| 2019-12-31 | CN¥3.50 Billion ≈ $511.99 Million |
+611.36% |
| 2018-12-31 | CN¥491.85 Million ≈ $71.97 Million |
+239.81% |
| 2017-12-31 | CN¥144.74 Million ≈ $21.18 Million |
+26.35% |
| 2016-12-31 | CN¥114.56 Million ≈ $16.76 Million |
-45.47% |
| 2015-12-31 | CN¥210.10 Million ≈ $30.74 Million |
+58.69% |
| 2014-12-31 | CN¥132.40 Million ≈ $19.37 Million |
+18.42% |
| 2013-12-31 | CN¥111.80 Million ≈ $16.36 Million |
-32.96% |
| 2012-12-31 | CN¥166.77 Million ≈ $24.40 Million |
+38.89% |
| 2011-12-31 | CN¥120.07 Million ≈ $17.57 Million |
-- |
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic… Read more